Home β€Ί Stock analysis β€Ί BGLC

BioNexus Gene Lab (BGLC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

BGLC dips 1.6% to $1.20, 4 down days in a row. Closed at $1.20, -1.63% vs the prior close of $1.22. Day range $1.20–$1.24, opened at $1.21.

Last close$1.20-1.63%
Day range1.20–1.24
Open1.21
Volume6.00K
52-week range1.07–5.89
Avg volume (20d)10.21K

BGLC daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” BGLC dips 1.6% to $1.20, 4 down days in a row
Oct 15, 2026 β€” BGLC slides 3.1% to $1.22, 3 down days in a row
Oct 14, 2026 β€” BGLC slides 4.5% to $1.26
Oct 13, 2026 β€” BGLC slides 5.0% to $1.32
Oct 12, 2026 β€” BGLC jumps 7.8% to $1.39
Oct 9, 2026 β€” BGLC jumps 3.3% to $1.29
Oct 8, 2026 β€” BGLC slides 6.8% to $1.25
Oct 7, 2026 β€” BGLC jumps 8.1% to $1.34 on 2.3x normal volume
Oct 6, 2026 β€” BGLC slides 3.1% to $1.24
Oct 5, 2026 β€” BGLC rises 0.8% to $1.28
Oct 2, 2026 β€” BGLC jumps 5.8% to $1.27

BGLC latest news & SEC filings

Every SEC filing by or about BGLC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 7, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001477932-26-006075

Aug 14, 2026 Β· Form SCHEDULE 13D β€” Activist-style stake (13D)

Activist-style stake (13D) β€” an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001520138-26-000354

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001520138-26-000349

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001520138-26-000348

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001520138-26-000347

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001520138-26-000346

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001520138-26-000345

Aug 14, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0001477932-26-005093

Aug 7, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001520138-26-000322

Jul 28, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001477932-26-004556

Things to know before you trade BGLC

BGLC market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20261.211.241.201.206.00K
Oct 15, 20261.201.221.191.224.20K
Oct 14, 20261.241.281.241.261.10K
Oct 13, 20261.331.331.201.328.40K
Oct 12, 20261.271.391.271.3918.60K
Oct 9, 20261.211.291.211.293.90K
Oct 8, 20261.331.331.251.251.10K
Oct 7, 20261.331.361.211.3427.50K
Oct 6, 20261.211.271.201.2418.00K
Oct 5, 20261.281.311.271.2811.80K
Oct 2, 20261.251.281.251.272.50K
Oct 1, 20261.281.431.201.2040.80K
Sep 30, 20261.281.281.161.229.10K
Sep 29, 20261.371.401.271.2715.00K
Sep 28, 20261.381.411.271.3011.40K
Sep 25, 20261.431.471.251.396.00K
Sep 24, 20261.501.501.441.483.10K
Sep 23, 20261.451.471.451.473.30K
Sep 22, 20261.481.481.451.461.70K
Sep 21, 20261.531.541.471.5010.70K

About BioNexus Gene Lab

BioNexus Gene Lab (BGLC) is listed on the Nasdaq and classified by the SEC under β€œServices-Medical Laboratories”. Its business address is in KUALA LUMPUR. State of incorporation: WY. Fiscal year ends December 31. SEC CIK 1737523.

BGLC board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Abdul Hamid Muhammad Azrul BinDirectorAug 14, 2026
Jook Yuen LowDirectorAug 14, 2026
Lee Su-Leng TanChief Executive OfficerAug 14, 2026
Chee Keong YapDirectorAug 14, 2026

Executive officers

NameTitleLatest filing
Set Fui ChongChief Financial OfficerAug 14, 2026
Lee Su-Leng TanChief Executive OfficerAug 14, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

BGLC financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$7.42M$-2.98Mβ€”$-1.84M
Dec 31, 2024$9.51M$-1.60M-0.09$-2.09M
Dec 31, 2023$9.77M$-2.63M-0.17$-1.82M
Dec 31, 2022$10.93M$-355.97Kβ€”$551.82K
Dec 31, 2021$13.36M$751.57Kβ€”$9.16K

Latest balance sheet: total assets $8.73M, total liabilities $947.98K, cash $1.23M (as of Jun 30, 2026).

BGLC earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Services-Medical Laboratories

Natera (NTRA)Guardant Health (GH)Quest Diagnostics (DGX)Labcorp (LH)Grail (GRAL)Caris Life Sciences (CAI)Celcuity (CELC)CareDx (CDNA)Veracyte (VCYT)BillionToOne (BLLN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on BGLC

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.